Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and parkinson's disease

Current Pharmaceutical Design

Volumn 14, Issue 14, 2008, Pages 1428-1434

  Asanuma, Masato ^a   Miyazaki, Ikuko ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase; Dopamine quinone; Inflammation; Neuroprotection; Nitric oxide; Nonsteroidal anti inflammatory drugs; Parkinson's disease; Peroxisome proliferator activated receptor

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DOPAMINE; IBUPROFEN; INDOMETACIN; KETOPROFEN; LEVODOPA; MEFENAMIC ACID; MELOXICAM; METHAMPHETAMINE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; QUINONE DERIVATIVE; ROFECOXIB; SALICYLATE SODIUM; TUMOR NECROSIS FACTOR ALPHA; VALDECOXIB;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; DISEASE MODEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSKINESIA; ENZYME INHIBITION; EXPERIMENTAL MODEL; HUMAN; INCIDENCE; LONG TERM CARE; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SEX DIFFERENCE; SUBSTANTIA NIGRA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HUMANS; MODELS, NEUROLOGICAL; MPTP POISONING; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; PPAR GAMMA; PREVALENCE;

EID: 47249142027     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784480153     Document Type: Review

References (112)

1. Gao HM, Liu B, Zhang W, Hong JS. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 2003; 24: 395-401.
2. Asanuma M, Miyazaki I, Diaz-Corrales FJ, Ogawa N. Quinone formation as dopaminergic neuron-specific oxidative stress in pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism. Acta Med Okayama 2004; 58: 221-33.
3. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substentia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38: 1285-91.
4. Knott C, Stern G, Wilkin GP. Inflammatory regulators in Parkinson's disease: INOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 2000; 16: 724-39.
5. Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines; and neurotrophins in Parkinson's disease. J Neural Transm Suppl 2000; 60: 277-90.
6. McGeer PL, Yasojima K, McGeer EG. Inflammation in Parkinson's disease. Adv Neurol 2001; 86: 83-9.
7. Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003; 53(Suppl 3): S49-58, S-60.
8. McGecr PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004; 10(Suppl 1): S3-7.
9. Ishida Y, Nagai A, Kobayashi S, Kim SU. Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase. J Neuropathol Exp Neurol 2006; 65: 66-77.
10. Hunot S, Brugg B, Ricard D, Michel PP, Muriel M-P, Ruberg M, et al. Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci USA 1997; 94: 7531-6.
11. Mirza B, Hadberg H, Thomsen P, Moos T. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 2000; 95: 425-32.
12. Castano A, Herrera AJ, Cano J, Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 1998; 70: 1584- 92.
13. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: Relevance to Parkinson's disease. J Neurochem 2002; 81: 1285-97.
14. Stern EL, Quan N, Proescholdt MG, Herkenham M. Spatiotemporal induction patterns of cytokine and related immune signal molecule mRNAs in response to intrastriatal injection of lipopolysaccharide. J Neuroimmunol 2000; 109: 245-60.
15. Arimoto T, Choi DY, Lu X, Liu M, Nguyen XV, Zheng N, et al. Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol Aging 2007; 28: 894-906.
16. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. The inflammatory reaction following 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999; 156: 50-61.
17. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 2007; 205: 295-312.
18. Kurkowska-Jastrzebska I, Litwin T, Joniec I, Ciesielska A, Przybylkowski A, Czlonkowski A, Czlonkowska A. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int Immunopharmacol 2004; 4: 1307-18.
19. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids. Neuron 1993; 11: 371-86.
20. Tocco G, Freire-Moar J, Schreiber SS, Sakhi SH, Aisen PS, Pasinetti GM. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: Implications for Alzheimer's disease. Exp Neurol 1997; 144: 339-49.
21. Hoozemans JJ, Rozenmuller AJ, Janssen I, De Groot CJ, Veerhuis R, Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol (Berl) 2001; 101: 2-8.
22. Hirst WD, Young KA, Newton P, Allport VC, Marriott DR, Wilkin GP. Expression of COX-2 by normal and reactive astrocytes in the adult rat central nervous system. Mol Cell Neurosci 1999; 13: 57-68.
23. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 2003; 100: 5473-8.
24. Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, Bing G. Cyclooxygenase-2 mediates activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflammation 2006; 3: 6.
25. de Meira Santos Lima M, Braga Reksidler A, Marques Zonata S, Bueno Machado H, Tufik S, Vital MA. Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res 2006; 1101: 117-25.
26. Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001; 39: 167-74.
27. Sanchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell AL, Isacson O. Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation 2004; 1: 6.
28. +-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J 2005; 19: 1134-6.
29. Tyurina YY, Kapralov AA, Jiang J, Borisenko GG, Potapovich AI, Sorokin A, et al. Oxidation and cytotoxicity of 6-OHDA are mediated by reactive intermediates of COX-2 overexpressed in PC12 cells. Brain Res 2006; 1093: 71-82.
30. Aubin N, Curet O, Deffois A, Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 1998; 71: 1635-42.
31. Sairam K, Saravanan KS, Banerjee R, Mohanakumar KP. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 2003; 966: 245-52.
32. Przybylkowski A, Kurkowska-Jastrzebska I, Joniec I, Ciesielska A, Czlonkowska A, Czlonkowski A. Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse. Brain Res 2004; 1019: 144-51.
33. Di Matteo V, Pierucci M, Di Giovanni G, Di Santo A, Poggi A, Benigno A, et al. Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: An in vivo microdialysis study. Brain Res 2006; 1095: 167-77.
34. Asanuma M, Miyasaki I. Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease? Exp Neurol 2007; 206: 172-8.
35. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993; 90: 7240-4.
36. 2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J 1993; 12:2005-15.
37. Simpson CS, Morris BJ. Activation of nuclear factor κB by nitric oxide in rat striatal neurones: Differential inhibition of the p50 and p65 subunits by dexamethasone. J Neurochem 1999; 73: 353-61.
38. O'Neill LAJ, Kaltschmidt C. NF-κB: A crucial transcription factor for glial and neuronal cell function. Trends Neurosci 1997; 20: 252-8
39. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994; 265: 956-9.
40. Frantz B, O'Neill EA. The effect of sodium salicylate and aspirin on NF-κB. Science 1995; 270: 2017-9.
41. Grilli M, Pizzi M, Memo M, Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science 1996; 274: 1383-5.
42. Sanchez de Miguel L, de Frutos T, Gonzalez-Fernandez F, del Pozo V, Lahoz C, Jimenez A, et al. Aspirin inhibits inducible nitric oxide synthase expression and tumour necrosis fitotor-α release by cultured smooth muscle cells. Eur J Clin Invest 1999; 29: 93-9.
43. Aeberhard EE, Henderson SA, Arabolos NS, Griscavage JM, Castro FE, Barrett CT, et al. Nonsteroidal anti-inflammatory drugs inhibit expression of the inducible nitric oxide synthase gene. Biochem Biophys Res Commun 1995; 208: 1053-9.
44. Farivar RS, Chobanian AV, Brecher P. Salicylate or aspirin inhibits the induction of the inducible nitric oxide synthase in rat cardiac fibroblasts. Circ Res 1996; 78: 759-68.
45. Kim H, Lee E, Shin T, Chung C, An N. Inhibition of the induction of the inducible nitric oxide synthase in murine brain microglial cells by sodium salicylate. Immunology 1998; 95: 389-94.
46. Du ZY, Li XY. Inhibitory effects of indomethacin on interleukin-1 and nitric oxide production in rat microglia in vitro. Int.J Immunopharmacol. 1999; 21: 219-25.
47. Lipton SA. Janus faces of NF-κB: Neurodestruction versus neuroprotection. Nat Med 1997; 3: 20-2.
48. Asanuma M, Nishibayashi-Asanuma S, Miyazaki I, Kohno M, Ogawa N. Neuroprotectivc effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem 2001; 76:1895-904.
49. Asanuma M, Miyazaki I. Nonsteroidal anti-inflaminatory drugs in Parkinson's disease: Possible involvement of quinone formation. Expert Rev Neurother 2006; 6: 1313-25.
50. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406-10.
51. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000; 20: 5709-14.
52. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 2001; 414: 212-6.
53. Jaradat MS, Wongsud B, Phornchirasilp S, Rangwala SM, Shams G, Sutton M, et al. Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol 2001; 62: 1587-95.
54. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
55. Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor γ (PPARγ) agonists. PPARγ co-association with transcription factor NFAT. J Biol Chem 2000; 275: 4541-4.
56. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-6.
57. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 2000; 403: 103-8.
58. Heneka MT, Feinstein DL, Galea E, Gleichmann M, Wullner U, Klockgether T. Peroxisome proliferator-activated receptor γ agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J Neuroimmunol 1999; 100: 156-68.
59. Heneka MT, Klockgether T, Feinstein DL. Peroxisome proliferator-activated receptor-γ ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 2000; 20: 6862-7.
60. Kitamura Y, Kakimura J, Matsuoka Y, Nomura Y, Gebicke-Haerter PJ, Taniguchi T. Activators of peroxisome proliferator-activated receptor-γ (PPARγ) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells. Neurosci Lett 1999; 262: 129-32.
61. 12,14-prostaglandin J2 in the regulation of microglial functions. Eur J Neurosci 2000; 12: 2215-23
62. Landreth GE, Heneka MT. Anti-inflammatory actions of peroxisome proliferator-activated receptor γ agonists in Alzheimer's disease. Neurobiol Aging 2001; 22: 937-44.
63. Kielian T, Drew PD. Effects of peroxisome proliferator-activated receptor-γ agonists on central nervous system inflammation. J Neurosci Res 2003; 71: 315-25.
64. Elsisi NS, Darling-Reed S, Lee EY, Oriaku ET, Soliman KF. Ibuprofen and apigenin induce apoptosis and cell cycle arrest in activated microglia. Neurosci Lett 2005; 375: 91-6.
65. Ferger B, Teismann P, Earl CD, Kuschinsky K, Oertel WH. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch Pharmacol 1999; 360: 256-61.
66. Mohanakumar KP, Muralikrishnan D, Thomas B. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity. Brain Res 2000; 864: 281-90.
67. Kurkowska-Jastrzebska I, Babiuch M, Joniec I, Przybylkowski A, Czlonkowski A, Czlonkowska A. Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. Int Immunopharmacol 2002; 2: 1213-8.
68. Klivenyi P, Gardian G, Calingasan NY, Yang L, Beal MF. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Mol Neurosci 2003; 21: 191-8.
69. Maharaj DS, Saravanan KS, Maharaj H, Mohanakumar KP, Daya S. Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Neurochem Int 2004; 44: 355-60.
70. +-induced degeneration: An in vivo microdialysis study. Ann N Y Acad Sci 2006; 1089: 462-71.
71. +-induced mitochondrial damage and superoxide anion generation. Life Sci 2006; 78: 2438-43.
72. Casper D, Yaparpalvi U, Rempel N, Werner P. Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett 2000; 289: 201-4.
73. +: Protection by acetylsalicylic acid aspirin. Parkinsonism Relat Disord 2002; 8: 407-11.
74. +: Differential requirement for neuronal cyclooxygenase activity. J Neurosci Res 2005; 81: 121-31.
75. + in PC12 cells. J Pharmacol Exp Ther 2004; 310:800-7.
76. Chae SW, Bang YJ, Kim KM, Lee KY, Kang BY, Kim EM, et al. Role of cyclooxygenase-2 in tetrahydrobiopterin-induced dopamine oxidation. Biochem Biophys Res Commun 2007; 359: 735-41.
77. Zhang X, Dong F, Mayer GE, Bruch DC, Ren J, Culver B. Selective inhibition of cyclooxygenase-2 exacerbates methamphetamine-induced dopamine depletion in the striatum in rats. Neuroscience 2007; 150: 950-8.
78. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002; 82: 615-24.
79. Berman SB, Hastings TG. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 1999; 73: 1127-37
80. Li H, Dryhurst G. Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)- 3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): A putative nigral endotoxin of relevance to Parkinson's disease. J Neurochem. 1997; 69: 1530-41.
81. Asanuma M, Miyazaki I, Ogawa N. Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 2003; 5: 165-76.
82. Choi HJ, Kim SW, Lee SY, Hwang O. Dopamine-dependent cytotoxicity of tetrahydrobiopterin: A possible mechanism for selective neurodegeneration in Parkinson's disease. J Neurochem 2003; 86: 143-52.
83. Choi HJ, Lee SY, Cho Y, Hwang O. Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: Relevance to Parkinson's disease. Neurochem Int 2005; 46: 329-35.
84. Machida Y, Chiba T, Takayanagi A, Tanaka Y, Asanuma M, Ogawa N, et al. Common anti-apoptotic roles of parkin and α-synuclein in human dopaminergic cells. Biochem Biophys Res Commun 2005; 332: 233-40.
85. LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ. Dopamine covalently modifies and functionally inactivates parkin. Nat Med 2005; 11: 1214-21.
86. Miyazaki I, Asanuma M, Diaz-Corrales FJ, Fukuda M, Kitaichi K, Miyoshi K, et al. Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone formation-related molecules. FASEB J 2006; 20: 571-3.
87. Sulzer D, Bogulavsky J, Larsen KE, Behr G, Karatekin E, Kleinman MR, et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci USA 2000; 97:11869-74.
88. Sulzer D, Zecca L. Intraneuronal dopamine-quinone synthesis: A review. Neurotox Res 2000; 1: 181-95.
89. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978; 14: 633-43
90. Tse TC, McCreery RL, Adams RN. Potential oxidative pathways of brain catecholamines. J Med Chem 1976; 19: 37-40.
91. Korytowski W, Sarna T, Kalyanaraman B, Sealy RC. Tyrosinase-catalyzed oxidation of dopa and related catechol(amine)s: A kinetic electron spin resonance investigation using spin-stabilization and spin label oximetry. Biochim Biophys Acta 1987; 924: 383-92.
92. Rosei MA, Blarzino C, Foppoli C, Mosca L, Coccia R. Lipoxy-genase-catalyzed oxidation of catecholamines. Biochem Biophys Res Commun 1994; 200: 344-50.
93. Hastings TG. Enzymatic oxidation of dopamine: The role of prostaglandin H synthase. J Neurochem 1995; 64: 919-24.
94. Foppoli C, Coccia R, Cini C, Rosei MA. Catecholamines oxidation by xanthine oxidase. Biochim Biophys Acta 1997; 1334: 200-6.
95. Fornstedt B, Rosengren E, Carlsson A. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine dopa and dopac in the brains of eight mammalian species. Neuropharmacology, 1986; 25: 451-4.
96. Ito S, Fujita K. Conjugation of dopa and 5-S-cysteinyldopa with cysteine mediated by superoxide radical. Biochem Pharmacol 1982; 31: 2887-9.
97. Xu-T, Stokes AH, Roskoski RJ, Vrana KE. Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neurosci Res 1998; 54: 691-7.
98. Kuhn DM, Arthur REJ, Thomas DM. Elferink LA. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: Possible relevance to Parkinson's disease. J Neurochem 1999; 73: 1309-17.
99. Whitehead RE, Ferrer JV, Javitch JA, Justice JB. Reaction of oxidized dopamine with endogenous cystaine residues in the human dopamine transporter. J Neurochem 2001; 76: 1242-51.
100. Haque ME, Asanuma M, Higashi Y, Miyazaki I, Tanaka K, Ogawa N. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim Biophys Acta 2003; 1619: 39-52.
101. Izumi Y, Sawada H, Yamamoto N, Kume T, Katsuki H, Shimohama S, et al. Iron accelerates the conversion of dopamineoxidized intermediates into melanin and provides protection in SH-SY5Y cells. J Neurosci Res 2005; 82: 126-37.
102. Izumi Y, Sawada H, Sakka N, Yamamoto N, Kume T, Katsuki H, et al. p-Quinone mediates 6-hydroxdopamine-induced dopaminergic neuronal death and ferrous iron accelerates the conversion of p-quinone into melanin extracellularly. J Neurosci Res 2005; 79: 849-60.
103. Olanow CW, Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis-targeted disease-modifying strategy. Mov Disord 2005; 20(Suppl. 11): S3-10.
104. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl. J Med 2004; 351: 2498-508.
105. Mattammal MB, Strong R, Lakshmi VM, Chung HD, Stephenson AH. Prostaglandin H synthetase-mediated metabolism of dopamine: Implication for Parkinson's disease. J Neurochem 1995; 64: 1645-54.
106. Cheng FC, Kuo JS, Chia LG, Dryhurst G. Elevated 5-S-cysteinyldopamine/ homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: Possible markers for and potential insights into the pathoetiology of Parkinson's disease. J Neural Transm 1996; 103: 433-46.
107. Spencer JP, Jenner P, Daniel SE, Lees AJ, Marsden DC, Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: Possible mechanisms of formation involving reactive oxygen species. J Neurochem 1998; 71: 2112-22.
108. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003; 60: 1059-64.
109. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005; 58: 963-7.
110. Hernan MA, Logroscino G, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 2006; 66: 1097-9.
111. Bower JH, Maraganore DK Peterson BJ, Ahlskog JE, Rocca WA. Immunologic doseases, anti-inflammatory drugs, and Parkinson disease: A case-control study. Neurology 2006; 67: 494-6.
112. Ton TG, Heckbert SR, Longstreth WTJ, Rossing MA, Kukull WA, Franklin GM, et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord 2006; 21: 964-9.